TICKERNERD
Menu
SABSHealthcare · Biotechnology

SABS Stock Forecast: SAB Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$3.89
+1.04% on the day

The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. hold a median 12-month price target of $12 — +208.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 8 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$298.2M
Ticker Nerd rank
35 / 100
Median analyst target
$12
Analysts covering
11
Total return, dividends reinvested
1W
+9.0%
1M
−0.3%
YTD
+4.0%
1Y
+74.4%
From 52W high
−15.3%
From 52W low
+99.5%
$1.95
$4.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SABS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SAB Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Momentum
74
Quality
69
Size
59
Growth
51
Value
33
Issuance
33
Revisions
29
Accruals
14

Volatility (77): The share price has been relatively steady.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

The rank is the raw material. Whether the rules would actually own SAB Biotherapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

SABS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SABS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26SABSHigh $16Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $6Median $12High $16

The green dot is the last close — the median target sits +208.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 June 2026BarclaysInitiatesOverweight$13
17 June 2026Chardan CapitalMaintainsBuy$14 → $16
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026Leerink PartnersMaintainsOutperform—
22 May 2026CitigroupInitiatesBuy—
20 May 2026JefferiesInitiatesBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026Rodman & RenshawReiteratesBuy—
2 Apr 2026Rodman & RenshawInitiatesBuy—
11 Mar 2026Chardan CapitalMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
19 Dec 2025GuggenheimInitiatesBuy—
18 Dec 2025Chardan CapitalMaintainsBuy—
17 Nov 2025Chardan CapitalMaintainsBuy—
19 Sept 2025Chardan CapitalMaintainsBuy—
17 Sept 2025Leerink PartnersInitiatesOutperform—
8 Aug 2025Chardan CapitalMaintainsBuy—
22 July 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

SABS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

SAB Biotherapeutics, Inc. (SABS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.3×

Cheaper than 45% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 64% of US stocks

EV / EBITDA
−3.7×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−11.3%

Higher than 35% of US stocks

Return on assets
−33.5%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SABS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SABSSAB Biotherapeutics, Inc.$298.2M
35
FHTXFoghorn Therapeutics, Inc.$355.6M
74
IPSCCentury Therapeutics, Inc.$359.3M
44
PALIPalisade Bio, Inc.$350.0M
45
LYELLyell Immunopharma, Inc.$360.5M
66
GALTGalectin Therapeutics, Inc.$347.9M
51
DMACDiaMedica Therapeutics, Inc.$363.7M
39
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SABS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest SABS news & analysis

SAB Biotherapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

During its Q2 earnings call, SAB Biotherapeutics said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.

Why it matters — The update reaffirms the expected clinical development timeline for SAB-142, the company's lead candidate, which is central to SABS watchers following its progress.

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

GlobeNewsWire · 6 Aug 2026positive

SAB Biotherapeutics reported its Q2 2026 financial results and provided business updates. Over 60 clinical sites have been activated in the registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes, with enrollment on track for completion in Q4 2026 and topline data expected in 2H 2027. The company also noted a grant to the PRISE-hATG study and an operational runway through 2028.

Why it matters — The update confirms SAB-142's SAFEGUARD trial is progressing on schedule with expanded site activation and funding that supports operations through 2028, providing clarity on key clinical milestones ahead.

FAQ

Frequently asked questions about SABS stock

What is the SABS stock price forecast for 2026-2027?

The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SABS stock a buy right now?

Of the 11 analysts covering SAB Biotherapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SAB Biotherapeutics, Inc. 35 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SABS?

As at 8 Aug 2026, SAB Biotherapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will SABS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +208.5% from the last close, and Ticker Nerd's factor model ranks SAB Biotherapeutics, Inc. 35 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SABS stock forecast for 2030?

No analyst covering SAB Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SABS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.

How has SABS stock performed over the past year?

SAB Biotherapeutics, Inc. returned +74.4% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SAB Biotherapeutics, Inc. do?

Sab Biotherapeutics Inc. is a biotechnology company dedicated to developing advanced immunotherapies through its innovative platform for producing polyclonal antibodies.

What is the latest news on SABS?

The most recent item we track (MarketBeat, 7 Aug 2026): "SAB Biotherapeutics Q2 Earnings Call Highlights". During its Q2 earnings call, SAB Biotherapeutics said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.

Company

About SAB Biotherapeutics, Inc.

Sab Biotherapeutics Inc. is a biotechnology company dedicated to developing advanced immunotherapies through its innovative platform for producing polyclonal antibodies. The primary purpose of the company is to harness the power of the human immune system to treat and prevent a wide range of infectious diseases and immune system disorders. Sab Biotherapeutics has developed a proprietary technology that uses transgenic cattle to produce fully human antibodies, offering a scalable and efficient process to meet the demand for antibody therapies. Notably, the company's approach enables rapid response to emerging pathogens, making it a key player in the global health sector where infectious disease outbreaks pose significant challenges. Its technology holds promise across various therapeutic areas, from combating infectious diseases to addressing autoimmune conditions and even offering solutions in oncology. In the financial markets, Sab Biotherapeutics represents a growing segment of biotech firms dedicated to biopharmaceutical innovations. The company’s advancements contribute to the evolving landscape of therapeutic solutions, highlighting the potential for biotechnology to revolutionize treatment paradigms and enhance public health resilience.

CEO Mr. Samuel J. Reich · 86 employees · United States · https://www.sab.bio